The U.S. Supreme Court yesterday declined to review W.L. Gore‘s infringement loss to C.R. Bard (NYSE:BCR) over stent graft patents, leaving Gore on the hook for more than $1 billion in damages owed to Bard. After the Federal Circuit Appeals Court in January upheld a judgment of willful infringement, tacking on an extra $205 million to the $854 million already […]
W.L. Gore & Associates
Bard, Gore score wins in 2nd stent graft case
W.L. Gore & Associates and C.R. Bard (NYSE:BCR) split a round in their 2nd battle over stent graft patents, according to court documents unsealed yesterday, as Gore appeals its $1 billion loss in another stent graft case to the U.S. Supreme Court. In that case, dating back to the 1970s, Bard alleged that Gore infringed a stent […]
Gore asks U.S. Supreme Court to revisit $1B loss to Bard
W.L. Gore & Associates asked the U.S. Supreme Court to revisit its $1 billion infringement loss to C.R. Bard (NYSE:BCR) over stent graft patents, saying the high court should determine whether patents must be conveyed in writing. Gore is on the hook for more than $1 billion in damages owed to Murray Hill, N.J.-based Bard, after […]
Gore pays $208.9 million in enhanced damages owed to C.R. Bard | Medtech legal news for the week of May 11, 2015
Gore ponies up $209m in Bard loss
Court upholds NUVA patent win over MDT | Medtech legal news for the week of April 20, 2015
Appeals court won’t revisit Bard’s $1B win over W.L. Gore
Gore on the hook for $1B in damages to Bard | Medtech legal news for the week of January 19, 2015
Appeals court puts Gore on the hook for $1B in damages to Bard
Gore lands CE Mark for Viabahn vascular device
Gore Medical said it received CE Mark approval for its Viabahn vascular device for the treatment of obstructed peripheral veins in hemodialysis patients.
The Flagstaff, Ariz.-based company said the approval covers the treatment of obstructed peripheral veins, excluding the venae cavae and pulmonary veins.